P051 Real-world experience of change in lung clearance index (LCI2.5) following initiation of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis aged 6 through 11

H Dowle,T Gilchrist,K Moffat,J Forster,K.A Macleod,D.S Urquhart

doi:10.1016/s1569-1993(23)00426-5

P051 Real-world experience of change in lung clearance index (LCI2.5) following initiation of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis aged 6 through 11

H Dowle, T Gilchrist + Show 4 more

https://doi.org/10.1016/s1569-1993(23)00426-5

Copy DOI

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Publication Date: Jun 1, 2023

Affiliation: Royal Hospital for Children, University of Edinburgh

#Change In Lung Clearance Index #Lung Clearance Index + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Objectives: Elexacaftor/tezacaftor/ivacaftor (ETI) was licensed for use in Scotland in January 2022 for children aged between 6–11 years with CF and any FDA approved mutation combination. This single-centre, cohort study aimed to analyse the effects of ETI on lung health (LCI2.5) as well as spirometry and growth measures.

Full Text